Evaluating safety and quality of robotic-assisted gastric cancer surgery: meta-analysis and meta-regression

评估机器人辅助胃癌手术的安全性和质量:荟萃分析和荟萃回归

阅读:1

Abstract

BACKGROUND: Robotic-assisted surgery is expanding globally. The UK's National Institute for Health and Care Excellence recently cautioned due to a paucity of high-quality evidence. To address this, a systematic review, meta-analysis, and meta-regression were undertaken to evaluate the quality and safety of robotic-assisted gastrectomy (RAG) versus conventional approaches for gastric cancer. METHODS: Systematic searches were conducted on MEDLINE, Embase, Web of Science, and Scopus (2 May 2025) for studies comparing RAG to open or laparoscopic gastrectomy up to 30 April 2025. Primary outcomes were Clavien-Dindo grade ≥ II complications (CD ≥ II; safety) and margin-positive resections (quality). Risk of bias was assessed using the Risk Of Bias In Non-randomized Studies of Interventions and Cochrane Risk of Bias v2.0 tools. Heterogeneity and evidence certainty were evaluated using meta-regression and GRADE assessment. RESULTS: In all, 90 studies (65 296 patients) were included; only three studies were randomized clinical trials and 72 were from East Asia. In 44 studies (12 102 patients) RAG was associated with significantly lower CD ≥ II complications (odds ratio (OR) 0.74; 95% confidence interval (c.i.) 0.64 to 0.86); heterogeneity was low (I2 = 21.4%). Seven studies had a low risk of bias. From 35 studies on margin status, RAG had fewer R1 resections (OR 0.74; 95% c.i. 0.51 to 1.07); heterogeneity was moderate (I2 = 34.0%). Adoption year, industry funding, extent of resection, and tumour stage were identified as sources of heterogeneity. Three studies were at low risk of bias. Certainty was very low for both outcomes. CONCLUSION: Although there may be potential benefits of robotic-assisted surgery, cautious adoption is warranted given the current uncertainty. Safe adoption requires standardized training, competency benchmarks, and limiting industry involvement. High-quality evaluation through randomized trials and parallel health economics is urgently needed to inform future policy and practice.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。